Open Access

Sunitinib potentiates the cytotoxic effect of electrochemotherapy in pancreatic carcinoma cells

,

,

Bostjan Markelc

Markelc, Bostjan

,

,

and

Mar 28, 2022

Sunitinib potentiates the cytotoxic effect of electrochemotherapy in pancreatic carcinoma cells's Cover Image

Radiology and Oncology

Volume 56 (2022): Issue 2 (June 2022)

About this article

Previous Article

Cite

Share

Download Cover

Article Category: Research Article

Published Online: Mar 28, 2022

Page range: 164 - 172

Received: Feb 10, 2022

Accepted: Mar 02, 2022

DOI: https://doi.org/10.2478/raon-2022-0009

Keywords
electrochemotherapy, ECT, pancreas, sunitinib, bleomycin, tyrosine-kinase inhibitors, pancreatic cancer

© 2022 Masa Bosnjak, Tanja Jesenko, Bostjan Markelc, Anja Cerovsek, Gregor Sersa, Maja Cemazar, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Survival fraction of BxPC-3 cells after electrochemotherapy (ECT). Survival of cells treated with ECT with bleomycin after 3 days (A) and 7 days (B) and survival fraction of BxPC-3 cells treated with ECT with cisplatin after 3 (C) and 7 days (D). The values are presented as the AM ± SEM. *p < 0.05 vs. untreated control cells, n = 3.

Targeted therapy of BxPC-3 pancreatic carcinoma cells with sunitinib. (A) Expression of different tyrosine kinases as sunitinib targets; n = 2. Surviving fraction of BxPC-3 cells treated with different sunitinib concentrations incubated for (B) 3 and (C) 7 days. The values are presented as the AM ± SEM. *p < 0.05 vs. untreated control cells, n = 3.
FLT1 = fms related receptor tyrosine kinase 1/VEGFR1; FLT3 = fms related receptor tyrosine kinase 3; KDR = kinase insert domain receptor/VEGFR2; KIT = KIT proto-oncogene; RET = ret proto-oncogene; PDGFR = platelet-derived growth factor receptor — Targeted therapy of BxPC-3 pancreatic carcinoma cells with sunitinib. (A) Expression of different tyrosine kinases as sunitinib targets; n = 2. Surviving fraction of BxPC-3 cells treated with different sunitinib concentrations incubated for (B) 3 and (C) 7 days. The values are presented as the AM ± SEM. *p < 0.05 vs. untreated control cells, n = 3. FLT1 = fms related receptor tyrosine kinase 1/VEGFR1; FLT3 = fms related receptor tyrosine kinase 3; KDR = kinase insert domain receptor/VEGFR2; KIT = KIT proto-oncogene; RET = ret proto-oncogene; PDGFR = platelet-derived growth factor receptor

Surviving fraction of BxPC-3 cells treated with ECT monotherapy with bleomycin (A) or cisplatin (B) combined with 2.5, 5 or 7.5 μM sunitinib. The values are presented as the AM ± SEM. *p < 0.05 statistically significant difference vs. annotated groups, n = 3.

The combination of ECT with bleomycin and sunitinib resulted in a higher number of dead cells. (A) Number of dead cells detected every 4 hours during kinetic measurement (A) after ECT single treatment, (B) after addition of 2.5, 5 or 7.5 μM sunitinib to Ctrl, (C) after addition of 2.5, 5 or 7.5 μM sunitinib to EP and (D) after addition of 2.5, 5 or 7.5 μM sunitinib to ECT. The values are presented as the AM ± SEM. *p < 0.05 vs. annotated groups, n = 3.
Ctrl = untreated control cells; ECT = electrochemotherapy; EP = electroporated cells only — The combination of ECT with bleomycin and sunitinib resulted in a higher number of dead cells. (A) Number of dead cells detected every 4 hours during kinetic measurement (A) after ECT single treatment, (B) after addition of 2.5, 5 or 7.5 μM sunitinib to Ctrl, (C) after addition of 2.5, 5 or 7.5 μM sunitinib to EP and (D) after addition of 2.5, 5 or 7.5 μM sunitinib to ECT. The values are presented as the AM ± SEM. *p < 0.05 vs. annotated groups, n = 3. Ctrl = untreated control cells; ECT = electrochemotherapy; EP = electroporated cells only

Language:: English

Publication timeframe:: 4 times per year
Journal Subjects:: Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology

Journal RSS Feed